Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
50.5M
-
Shares change
-
+785K
-
Total reported value, excl. options
-
$2.2B
-
Value change
-
-$8.89M
-
Put/Call ratio
-
1.16
-
Number of buys
-
78
-
Number of sells
-
-83
-
Price
-
$43.48
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2018
198 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.5M shares
of 96M outstanding shares and own 52.68% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6M shares), Capital Research Global Investors (5.86M shares), Capital International Investors (4.59M shares), BlackRock Inc. (4.48M shares), Vanguard Group Inc (4.16M shares), FMR LLC (2.95M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.73M shares), STATE STREET CORP (2.05M shares), Capital World Investors (1.58M shares), and FIRST TRUST ADVISORS LP (1.47M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.